Skip to main content
. 2015 Apr 9;64(7):2409–2419. doi: 10.2337/db14-1708

Figure 3.

Figure 3

GLP-1(32-36)amide administration improves insulin sensitivity in DIO mice. A: Plasma glucose levels during an intraperitoneal glucose tolerance test (ipGTT) in mice fed an HFD for 24 weeks and 16 weeks of continuous infusions of vehicle or GLP-1(32-36)amide (n = 5–6 per group). #P < 2.8E-04; *P < 0.0058; **P < 0.0028; ##P < 1.9E-05; ***P < 0.0018; ****P < 0.0014, peptide vs. vehicle. Right upper panel: Quantification of AUC for the total glycemic excursions (n = 5–6 per group). *P < 0.046. Right lower panel: Plasma insulin concentrations obtained 10 min after glucose administration (n = 5–6 per group). B: Plasma glucose levels during an insulin tolerance test (ITT) in mice fed an HFD for 38 weeks and 19 weeks of continuous infusions of vehicle or GLP-1(32-36)amide (n = 4 per group). ***P < 1.2E-03; **P < 2.05E-03; ****P < 0.09E-03; *P < 1.3E-03, peptide vs. vehicle. Right panel: Quantification of AUC for the total glycemic excursions (n = 4 per group). *P < 0.02.